Drugs / Isoprenaline
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06473116 | Mar 2025 → Jul 2029 expected | cardiac arrest | University of Southern Denmark | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06082388 Comparator | Nov 2023 → Sep 2025 | cardiac rhythm disease | Medical University of Lodz | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoprenaline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06473116 ↗ |
| Action | Activate | “Isoprenaline is a preferential agonist of beta-1-adrenergic receptors.” NCT06082388 ↗ |
| Route | Intravenous | “Continuous i.v. infusion of 0.01 mcg/kg b.w./min will be administered to reach the increase of heart rate of 25% or up to 130/min.” NCT06082388 ↗ |